Characterization of GSK′963: A Structurally Distinct, Potent and Selective Inhibitor of RIP1 Kinase

Cell Death Discovery - United Kingdom
doi 10.1038/cddiscovery.2015.9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Characterization of Structurally Distinct, Isoform-Selective Phosphoinositide 3'-Kinase Inhibitors in Combination With Radiation in the Treatment of Glioblastoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor

Cancer Science
Cancer ResearchMedicineOncology
2018English

Nonclinical and Clinical Pharmacological Characterization of the Potent and Selective Cathepsin K Inhibitor MIV-711

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2018English

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Inhibition of Angiogenesis by Staurosporine, a Potent Protein Kinase Inhibitor.

Journal of Antibiotics
Drug DiscoveryPharmacology
1992English

Development of Potent and Selective PfCLK3 Inhibitors Based on GSK-TCMDC151 as a New Class of Antimalarials

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy